+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Achromatopsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 128 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970406
The 7 major achromatopsia markets reached a value of US$ 106.2 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 181.4 Million by 2034, exhibiting a growth rate (CAGR) of 6.13% during 2023-2034.

The achromatopsia market has been comprehensively analyzed in this report titled "Achromatopsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Achromatopsia, also known as total color blindness, refers to a rare inherited eye disorder that affects an individual's ability to perceive colors. It is primarily caused by genetic mutations that impact the function of the cones in the retina, the light-sensitive cells responsible for color vision. As a result, individuals suffering from the illness experience complete or near-complete loss of color vision, seeing the world only in shades of black, white, and gray. The symptoms of achromatopsia include photophobia (extreme sensitivity to light), reduced visual acuity, and poor vision in bright lighting conditions. Due to the lack of color discrimination, patients often rely on contrast and brightness to navigate their surroundings. Diagnosing achromatopsia typically involves a comprehensive eye examination, visual acuity tests, and specialized color vision tests, such as the Farnsworth-Munsell 100 Hue Test, to assess color perception deficiencies. Genetic testing may also be conducted to identify specific gene mutations associated with the condition, aiding in confirming the diagnosis.

The increasing prevalence of mutations in genes like CNGA3, CNGB3, and GNAT2, which can lead to a lack of functional cone photoreceptor cells in the retina, is primarily driving the achromatopsia market. In addition to this, the rising utilization of specialized medications, such as carbonic anhydrase inhibitors and tinted lenses, that help to manage light sensitivity and reduce discomfort in individuals suffering from the ailment is creating a positive outlook for the market. Moreover, the widespread integration of physical and occupational therapies, as they focus on enhancing visual skills, adaptive techniques, and motor functions, is further bolstering the market growth. These procedures contribute to an improved quality of life and the development of essential abilities for daily living. Apart from this, the rising awareness and diagnosis of achromatopsia have fueled the market's expansion, prompting a surge in demand for effective treatments. Additionally, the adoption of innovative procedures, like optogenetics, which involves introducing light-sensitive proteins into the retina to restore vision, is also providing new avenues for treating the condition effectively. Furthermore, numerous advancements in gene therapy that aim to introduce functional genetic material into affected cells to correct the underlying genetic mutations are expected to drive the achromatopsia market during the forecast period.

This report provides an exhaustive analysis of the achromatopsia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for achromatopsia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the achromatopsia market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the achromatopsia market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the achromatopsia market

Competitive Landscape:

This report also provides a detailed analysis of the current achromatopsia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the achromatopsia market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the achromatopsia market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the achromatopsia market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of achromatopsia across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of achromatopsia by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of achromatopsia by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with achromatopsia across the seven major markets?
  • What is the size of the achromatopsia patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of achromatopsia?
  • What will be the growth rate of patients across the seven major markets?

Achromatopsia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for achromatopsia drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the achromatopsia market?
  • What are the key regulatory events related to the achromatopsia market?
  • What is the structure of clinical trial landscape by status related to the achromatopsia market?
  • What is the structure of clinical trial landscape by phase related to the achromatopsia market?
  • What is the structure of clinical trial landscape by route of administration related to the achromatopsia market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Achromatopsia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Achromatopsia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Achromatopsia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 Achromatopsia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Achromatopsia - Unmet Needs10 Achromatopsia - Key Endpoints of Treatment
11 Achromatopsia - Marketed Products
11.1 List of Achromatopsia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Achromatopsia - Pipeline Drugs
12.1 List of Achromatopsia Pipeline Drugs Across the Top 7 Markets
12.1.1 AAV - CNGB3 - MeiraGTx/Janssen Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AAV- CNGA3 - MeiraGTx/Janssen Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Achromatopsia - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Achromatopsia - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Achromatopsia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Achromatopsia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Achromatopsia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Achromatopsia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Achromatopsia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Achromatopsia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Achromatopsia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Achromatopsia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Achromatopsia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Achromatopsia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Achromatopsia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Achromatopsia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Achromatopsia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Achromatopsia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Achromatopsia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Achromatopsia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Achromatopsia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Achromatopsia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Achromatopsia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Achromatopsia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Achromatopsia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Achromatopsia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Achromatopsia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Achromatopsia - Access and Reimbursement Overview
16 Achromatopsia - Recent Events and Inputs From Key Opinion Leaders
17 Achromatopsia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Achromatopsia Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information